All posts tagged: placebo-controlled

CB1 and CB2 receptors play differential roles in early zebrafish locomotor development

Scientists found that blocking CB1 receptors and CB2-receptors in young zebrafish resulted in morphological deficits, reductions in heart rate, and non-inflated swim bladders. These findings indicate that the endocannabinoid system is pivotal to the development of the locomotor system in zebrafish, and that disturbances to the endocannabinoid system in early life may have detrimental effects.

The translation of these effects to humans is obviously not direct, but it is important for science to learn about safety and expected effects, to examine how chemistry interacts in petri dishes, how basic organic/animal functions are impacted in a living thing, and when the time is appropriate, to then assess any effects in humans

View this review (yellow link) or download:

This paper is also stored here:   http://bit.ly/2YfykgI      inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDCB1 and CB2 receptors play differential roles in early zebrafish locomotor development
read more

Video: The Endocannabinoid System

A simplified overview of the human side of the human-cannabis interaction system!

Built from the growing mountain of literature inside the CED Foundation Medical Cannabis Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDVideo: The Endocannabinoid System
read more

Cannabinoids and autoimmune diseases: A systematic review (Diabetes)

As it stands, there is no cure for Type 1 Diabetes Mellitus. But, some of us in the medical community are starting to wonder if cannabis could be a viable treatment option. Several studies already address this, with impressive findings, and now, A new mouse model study suggests that not only could CBD prevent Type 1 Diabetes, but it seems to also reduce symptoms after onset. 

Now researchers must determine the long term effects of CBD treatment. Watch a video summary below:

View this review (yellow link) or download:

This paper is also stored here:    http://bit.ly/2Y1paV5     inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDCannabinoids and autoimmune diseases: A systematic review (Diabetes)
read more

Supplementing Antipsychotics with CBD Enhances Psychotic Symptom Treatment

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

Most schizophrenia medications function by blocking the action of the dopamine D2 receptor and effectively treat positive psychotic symptoms, such as delusions or hallucinations, but fail to treat negative psychotic symptoms, such as lack of motivation or the lack of an ability to feel pleasure. Anecdotal evidence has pointed toward the potential for CBD to attenuate psychotic symptoms in conjunction with normally prescribed antipsychotics; additionally, CBD is not hypothesized to act on the D2 receptor, suggesting that it may afford unique advantages over anti-psychotics.

Researchers interested in further exploring this conducted the first known placebo-controlled CBD trial among schizophrenia patients. Although results did not suggest a potential for CBD to treat negative psychotic symptoms, in conjunction with antipsychotics, the CBD group experienced marked lower levels of positive psychotic symptoms. Both the placebo and CBD groups experienced equal levels of treatment-induced adverse events, suggesting that CBD is well-tolerated.

These results suggest that CBD may be effective in treating not only schizophrenia but also psychotic symptoms associated with Parkinson’s disease and THC-induced psychosis.

Additional Point: CBD has shown to act in a neuroprotective manner and reduce the psychoactive effects of THC, making it a viable option for patients who have experienced negative side effects with THC.

View this review (yellow link) or download:

This paper is also stored here:    http://bit.ly/2WztI04     inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDSupplementing Antipsychotics with CBD Enhances Psychotic Symptom Treatment
read more

Video: Cannabinoids, Internal States, and Anxiety

A new literature review summarizing the recent findings relating to cannabis and anxiety.

Researchers conclude that CBD and low-dose THC can cause relaxation and decrease anxiety and self-spun thoughts. Some studies show that high-dose THC can cause psychotic symptoms; however, studies also show that CBD can protect against those THC-induced symptoms. Therefore, using cannabis extracts with THC and CBD could be a safe way to reduce anxiety. 

View this review (yellow link) or download:

This paper is also stored here:     http://bit.ly/2JnOpss    inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDVideo: Cannabinoids, Internal States, and Anxiety
read more

Cannabis is a Safe and Effect for the Treatment of Fibromyalgia

Safety and Efficacy of Medical Cannabis in Fibromyalgia 

A recent study has concluded that cannabis is a safe and effective treatment for patients suffering from fibromyalgia symptoms.

Fibromyalgia is a disorder characterized by widespread pain, fatigue, and issues sleeping. Cannabis is well known for its ability to treat pain, especially in lieu of opioids as the side effects are minimal and the risk of addiction minimal. This study found that over 200 patients were greatly benefited by cannabis as it moderated their pain and improved their mood. Future studies should aim to directly compare cannabis-based treatment with the currently accepted methods of fibromyalgia treatment to validate efficacy. 

This study highlights how beneficial cannabis can be for those patients who are treatment-resistant for the general treatment of most disorders, especially when pain is involved. Cannabis has been proven to be much safer than opioids, and yet our lack of complete information, concerning the exact mechanisms of the endocannabinoid system and how different cannabinoids act on those mechanisms severely limits our ability to offer practical, novel therapies. Cannabis has previously been shown to be beneficial for treatment-resistant forms of epilepsy and depression, which holds promise when continuing to look for novel treatments for other disorders that have proven difficult to treat. 

View this review (yellow link) or download:

This paper is also stored here:     http://bit.ly/2XpsGJr    inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDCannabis is a Safe and Effect for the Treatment of Fibromyalgia
read more

Video: Cannabinoid Delivery Systems for Pain and Inflammation Treatment

A 2018 literature review summarizes the various ways patients can consume cannabis (orally, topically, etc.) and the pain reductions associated with each method. The review focuses on the treatment of multiple sclerosis, cancer, anorexia, arthritis, and other painful disorders.

View this review (yellow link) or download:

This paper is also stored here:    http://bit.ly/2TSZ2Wr     inside the CED Foundation Archive

Benjamin Caplan, MDVideo: Cannabinoid Delivery Systems for Pain and Inflammation Treatment
read more

Study Reveals that Flavanoids can act as Allergy Medications

Anti-histaminic Effects of Resveratrol and Silymarin on Human Gingival Fibroblasts

It has recently been revealed that the flavonoids resveratrol and silymarin have an anti-histaminic effect on human gingival fibroblasts (HGF). HGF are cells that compose part of the gum tissue in the oral cavity. Silymarin and resveratrol were already known to have anti-bacterial and anti-inflammatory properties, but a recently published study has now revealed that silymarin alone and a combination of the two flavonoids both provide novel therapeutic approaches for inflammation due to allergies.

View this review (yellow link) or download:

This paper is also stored here:    http://bit.ly/2Ff1lhW   inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDStudy Reveals that Flavanoids can act as Allergy Medications
read more

The Cannabinoid System is a Promising Source of Targets for Treating Pain

A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain ECS

The cannabinoid system provides momentum to develop cannabinoid-based medications to treat inflammatory and neuropathic pain as researchers continue to find promising therapeutic targets. These new targets may lead to the formation of novel pain-relief medications that may serve well to alleviate pain for those suffering from cancer, multiple sclerosis, and fibromyalgia. Cannabis-based pain medicine is also being researched for opioid-sparing effects and effectiveness in reducing the necessary dose of opioids.

View this review (yellow link) or download:

This paper is also stored here:  http://bit.ly/2FfLorA        inside the CED Foundation Archive

To explore related information, click the keywords below:


Benjamin Caplan, MDThe Cannabinoid System is a Promising Source of Targets for Treating Pain
read more

Medical Marijuana and Treatment of Pediatric Epilepsy Patients

Medical Marijuana in the Pediatric Population With Epilepsy—What You Should Know

A recent review has discussed the known benefits of treating children who are suffering from epilepsy with cannabis-based medicine. Medical marijuana (MM) is a viable option for treating this population that comes with risks due to the high that comes from THC and its legal status as a Schedule 1 drug. The legal status is currently preventing larger scale research to be done so that physicians can better educate parents on how to care for a child taking MM.

View this review (yellow link) or download:

This paper is also stored here:     http://bit.ly/2KNbGVS    inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDMedical Marijuana and Treatment of Pediatric Epilepsy Patients
read more